Pl find enclosed Audited Financial Results along with auditors report for FY ended 31st march 26
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories reported consolidated revenue of Rs 147,123 million for FY2026, up 13.5% from Rs 129,645 million in FY2025. Profit after tax (attributable to owners) grew 6.3% to Rs 23,018 million from Rs 21,655 million. The company declared a total dividend of Rs 53 per share (Rs 43 interim already paid plus Rs 10 final). Exceptional items of Rs 1,748 million included impairment of real estate investments (Rs 747 million), labour code compliance costs (Rs 1,131 million), partially offset by gain on Indore facility sale (Rs 143 million). Auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion on both standalone and consolidated results. Borrowings increased significantly with current borrowings rising to Rs 11,311 million from Rs 7,519 million.
The stock delivered solid revenue and profit growth though below high-growth thresholds. The clean auditor opinion and dividend declaration are positive signals. However, the significant exceptional items related to real estate impairment and labour code compliance costs reduced profitability, and rising borrowings warrant monitoring.